Jo, Hitomi
Yoshida, Tatsuya http://orcid.org/0000-0003-4896-5824
Horinouchi, Hidehito
Yagishita, Shigehiro
Matsumoto, Yuji
Shinno, Yuki
Okuma, Yusuke
Goto, Yasushi
Yamamoto, Noboru
Takahashi, Kazuhisa
Motoi, Noriko
Ohe, Yuichiro
Article History
Received: 9 March 2021
Accepted: 19 June 2021
First Online: 27 June 2021
Declaration
:
: HJ has nothing to disclose. TY reports grants from ONO Pharmaceutical, during the conduct of the study; grants and personal fees from AstraZeneca, grants and personal fees from Bristol Myers Squibb, grants from Takeda, personal fees from Chugai, personal fees from Novartis, grants from MSD, grants from AbbVie, outside the submitted work; HH reports grants and personal fees from BMS, grants and personal fees from MSD, grants and personal fees from Chugai, grants and personal fees from Taiho, grants and personal fees from AstraZeneca, grants from Astellas, grants from Merck Serono, grants from Genomic Health, grants and personal fees from Lilly, grants and personal fees from Ono, outside the submitted work; SY has grants from Nippon Boehringer Ingelheim. YM reports grants from National Cancer Center Research and Development Fund, grants from Grant-in-Aid for Scientific Research on Innovative Areas, grants from Hitachi, Ltd., grants from Hitachi High-Technologies, personal fees from Olympus, personal fees from AstraZeneca, personal fees from Novartis, personal fees from COOK, personal fees from AMCO INC., outside the submitted work; YS has nothing to disclose. YO reports personal fees from AstraZeneca K.K., personal fees from Nippon Boehringer Ingelheim, personal fees from Eli Lilly K.K., personal fees from MSD K.K., personal fees from Chugai Pharma Co., Ltd, personal fees from Ono Pharma Co., Ltd, personal fees from Bristol Myers Squibb, outside the submitted work; YG reports grants and personal fees from Eli Lilly, grants and personal fees from Chugai, grants and personal fees from Taiho Pharmaceutical, personal fees from Boehringer Ingelheim, grants and personal fees from Pfizer, grants and personal fees from Novartis, personal fees from AstraZeneca, grants and personal fees from MSD, grants and personal fees from Guardant Health, grants and personal fees from Ono Pharmaceutical, grants from Kyorin, grants from Daiichi Sankyo, personal fees from Illumina, outside the submitted work; NY reports grants from Chugai, grants from Taiho, grants from Eisai, grants from Lilly, grants from Quintiles, grants from Astellas, grants from BMS, grants from Novartis, grants from Daiichi Sankyo, grants from Pfizer, grants from Boehringer Ingelheim, grants from Kyowa Hakko Kirin, grants from Bayer, grants from ONO PHARMACEUTICAL CO., LTD, grants from Takeda, personal fees from ONO PHARMACEUTICAL CO., LTD, personal fees from Chugai, personal fees from AstraZeneca, personal fees from Pfizer, personal fees from Lilly, personal fees from BMS, personal fees from Eisai, personal fees from Otsuka, personal fees from Takeda, personal fees from Boehringer Ingelheim, personal fees from Cimic, grants from Janssen Pharma, grants from MSD, grants from Merck, personal fees from Sysmex, grants from GSK, grants from Sumitomo Dainippon, outside the submitted work; KT reports grants and personal fees from Chugai Pharmaceutical Co., Ltd., grants and personal fees from Nippon Boehringer lngelheim Co., Ltd., grants and personal fees from MSD K.K, grants from Glaxo SmithKline Consumer Healthcare Japan K.K, grants from NIPPON SHINYAKU CO., LTD., grants from TSUMURA & CO., grants and personal fees from Pfizer Inc., personal fees from AstraZeneca K.K, grants and personal fees from TAIHO PHARMACEUTICAL CO., LTD., grants from DAIICHI SANKYO Co., LTD., grants from Astellas Pharma Inc., grants and personal fees from KYORIN Pharmaceutical Co., Ltd., grants from KYOWA Hakko Kirin Co., Ltd., grants from TEIJIN PHARMA LIMITED, grants from Sanofi K.K., grants and personal fees from ONO PHARMACEUTICAL CO., LTD., grants from Shionogi & Co., Ltd., personal fees from Bristol Myers Squibb Company, grants and personal fees from Novartis Pharma K.K, grants and personal fees from Eli Lilly Japan K.K, grants from Actelion Pharmaceuticals Japan Ltd., grants from NIPRO PHARMA CORPORATION, grants from Astellas Pharma lnc., grants from Takeda Pharmaceutical Company Limited., grants from Bayer Yakuhin, Ltd, grants from Torii Pharmaceutical Co., Ltd, personal fees from MSD K.K, personal fees from Meiji Seika Pharma Co, Ltd., outside the submitted work; NM reports grants and personal fees from Ono, personal fees from BMS, personal fees from MSD, personal fees from AstraZeneca, grants and personal fees from Roche Diagnostics, personal fees from Novartis, personal fees from Taiho, personal fees from Chugai, personal fees from Miraca Life Science, personal fees from Beckton Dickinson Japan, personal fees from Covidien Japan Inc, outside the submitted work; YO reports grants and personal fees from AstraZeneca, grants and personal fees from Bristol Myers Squibb, personal fees from Boehringer Ingelheim, grants and personal fees from Chugai, personal fees from Celltrion, personal fees from Amgen, grants and personal fees from Eli Lilly, from Janssen, grants and personal fees from Kyorin, grants and personal fees from Nippon Kayaku, grants and personal fees from Novartis, grants and personal fees from ONO Pharmaceutical, grants and personal fees from Pfizer, grants from Ignyta, grants and personal fees from Taiho, grants and personal fees from Takeda, outside the submitted work.
: Not required.
: This study was approved by an institutional review board (2015–355).